Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

282055

Tiragolumab-Tecentriq Combo for NSCLC Earns Breakthrough Therapy Status

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination of tiragolumab, a novel immunotherapy developed by Genentech, plus Tecentriq (atezolizumab) for the treatment of metastatic non-small cell lung cancer (NSCLC). The designation is intended to accelerate the development and review of medications that may be superior to existing therapies at treating serious life-threatening conditions. This one covers using the combination therapy as a first-line treatment for people…

You must be logged in to read/download the full post.